Genomic components of carcinogenesis

Rosemarie Schmandt, Gordon Mills

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Many of the genes encoding growth factors, growth factor receptors, enzymes, and other effector molecules that regulate normal cell growth are designated protooncogenes. Oncogenes, those genes associated with cellular transformation, differ from their protooncogenic progenitors by being mutated, overexpressed, or expressed at inappropriate times or locations in the cell. One of the activities of growth factors is to prime cells to undergo programmed cell death, which is characterized by a series of morphologic changes called apoptosis. In normal cells, specific mediators must be activated or suppressed to bypass programmed cell death. In tumor cells, either the pathways leading to apoptosis are not functional or the mediators that normally "rescue" cells from this fate are overexpressed or constitutively activated. In addition to the biochemical pathways that drive cell division, there are others that limit cell proliferation; these, designated tumor suppressors, anti-oncogenes, or recessive oncogenes, must be inactivated in normal cells to allow passage through the cell cycle and cell proliferation. In contrast to oncogenes, which are overexpressed or activated in tumors, tumor-suppressor genes are frequently inactivated in tumor cells, either by mutation or deletion. Thus, in normal cells a series of checks and balances must be overcome to allow initiation and continuation of cell division. In tumors, these processes are aberrant, resulting in increased rates of cell division, increases in the proportion of cells in the cell cycle, or increased survival of activated cells. Therefore, tumor cells frequently accumulate genomic alterations, which may result in the activation of a particular array of oncogenes, the inactivation of specific tumor-suppressor genes, and the bypassing of programmed cell death. Trials of antitumor agents that act by exploiting the overexpression of oncogenes in tumors and of the biochemical pathways by which they mediate cell proliferation are currently underway.

Original languageEnglish (US)
Pages (from-to)2375-2385
Number of pages11
JournalClinical Chemistry
Volume39
Issue number11 PART B
StatePublished - Dec 1 1993
Externally publishedYes

Fingerprint

Tumors
Carcinogenesis
Cells
Tumor Suppressor Genes
Cell proliferation
Oncogenes
Cell death
Neoplasms
Cell Division
Genes
Cell Death
Cell Proliferation
Intercellular Signaling Peptides and Proteins
Apoptosis
Cell Cycle
Gene encoding
Growth Factor Receptors
Cell growth
Antineoplastic Agents
Sequence Deletion

Keywords

  • Apoptosis
  • Growth factor receptors
  • Oncogenes
  • Tumor-suppressor genes

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Schmandt, R., & Mills, G. (1993). Genomic components of carcinogenesis. Clinical Chemistry, 39(11 PART B), 2375-2385.

Genomic components of carcinogenesis. / Schmandt, Rosemarie; Mills, Gordon.

In: Clinical Chemistry, Vol. 39, No. 11 PART B, 01.12.1993, p. 2375-2385.

Research output: Contribution to journalArticle

Schmandt, R & Mills, G 1993, 'Genomic components of carcinogenesis', Clinical Chemistry, vol. 39, no. 11 PART B, pp. 2375-2385.
Schmandt R, Mills G. Genomic components of carcinogenesis. Clinical Chemistry. 1993 Dec 1;39(11 PART B):2375-2385.
Schmandt, Rosemarie ; Mills, Gordon. / Genomic components of carcinogenesis. In: Clinical Chemistry. 1993 ; Vol. 39, No. 11 PART B. pp. 2375-2385.
@article{4c76b051cfb74f5f93129a14234f5783,
title = "Genomic components of carcinogenesis",
abstract = "Many of the genes encoding growth factors, growth factor receptors, enzymes, and other effector molecules that regulate normal cell growth are designated protooncogenes. Oncogenes, those genes associated with cellular transformation, differ from their protooncogenic progenitors by being mutated, overexpressed, or expressed at inappropriate times or locations in the cell. One of the activities of growth factors is to prime cells to undergo programmed cell death, which is characterized by a series of morphologic changes called apoptosis. In normal cells, specific mediators must be activated or suppressed to bypass programmed cell death. In tumor cells, either the pathways leading to apoptosis are not functional or the mediators that normally {"}rescue{"} cells from this fate are overexpressed or constitutively activated. In addition to the biochemical pathways that drive cell division, there are others that limit cell proliferation; these, designated tumor suppressors, anti-oncogenes, or recessive oncogenes, must be inactivated in normal cells to allow passage through the cell cycle and cell proliferation. In contrast to oncogenes, which are overexpressed or activated in tumors, tumor-suppressor genes are frequently inactivated in tumor cells, either by mutation or deletion. Thus, in normal cells a series of checks and balances must be overcome to allow initiation and continuation of cell division. In tumors, these processes are aberrant, resulting in increased rates of cell division, increases in the proportion of cells in the cell cycle, or increased survival of activated cells. Therefore, tumor cells frequently accumulate genomic alterations, which may result in the activation of a particular array of oncogenes, the inactivation of specific tumor-suppressor genes, and the bypassing of programmed cell death. Trials of antitumor agents that act by exploiting the overexpression of oncogenes in tumors and of the biochemical pathways by which they mediate cell proliferation are currently underway.",
keywords = "Apoptosis, Growth factor receptors, Oncogenes, Tumor-suppressor genes",
author = "Rosemarie Schmandt and Gordon Mills",
year = "1993",
month = "12",
day = "1",
language = "English (US)",
volume = "39",
pages = "2375--2385",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "11 PART B",

}

TY - JOUR

T1 - Genomic components of carcinogenesis

AU - Schmandt, Rosemarie

AU - Mills, Gordon

PY - 1993/12/1

Y1 - 1993/12/1

N2 - Many of the genes encoding growth factors, growth factor receptors, enzymes, and other effector molecules that regulate normal cell growth are designated protooncogenes. Oncogenes, those genes associated with cellular transformation, differ from their protooncogenic progenitors by being mutated, overexpressed, or expressed at inappropriate times or locations in the cell. One of the activities of growth factors is to prime cells to undergo programmed cell death, which is characterized by a series of morphologic changes called apoptosis. In normal cells, specific mediators must be activated or suppressed to bypass programmed cell death. In tumor cells, either the pathways leading to apoptosis are not functional or the mediators that normally "rescue" cells from this fate are overexpressed or constitutively activated. In addition to the biochemical pathways that drive cell division, there are others that limit cell proliferation; these, designated tumor suppressors, anti-oncogenes, or recessive oncogenes, must be inactivated in normal cells to allow passage through the cell cycle and cell proliferation. In contrast to oncogenes, which are overexpressed or activated in tumors, tumor-suppressor genes are frequently inactivated in tumor cells, either by mutation or deletion. Thus, in normal cells a series of checks and balances must be overcome to allow initiation and continuation of cell division. In tumors, these processes are aberrant, resulting in increased rates of cell division, increases in the proportion of cells in the cell cycle, or increased survival of activated cells. Therefore, tumor cells frequently accumulate genomic alterations, which may result in the activation of a particular array of oncogenes, the inactivation of specific tumor-suppressor genes, and the bypassing of programmed cell death. Trials of antitumor agents that act by exploiting the overexpression of oncogenes in tumors and of the biochemical pathways by which they mediate cell proliferation are currently underway.

AB - Many of the genes encoding growth factors, growth factor receptors, enzymes, and other effector molecules that regulate normal cell growth are designated protooncogenes. Oncogenes, those genes associated with cellular transformation, differ from their protooncogenic progenitors by being mutated, overexpressed, or expressed at inappropriate times or locations in the cell. One of the activities of growth factors is to prime cells to undergo programmed cell death, which is characterized by a series of morphologic changes called apoptosis. In normal cells, specific mediators must be activated or suppressed to bypass programmed cell death. In tumor cells, either the pathways leading to apoptosis are not functional or the mediators that normally "rescue" cells from this fate are overexpressed or constitutively activated. In addition to the biochemical pathways that drive cell division, there are others that limit cell proliferation; these, designated tumor suppressors, anti-oncogenes, or recessive oncogenes, must be inactivated in normal cells to allow passage through the cell cycle and cell proliferation. In contrast to oncogenes, which are overexpressed or activated in tumors, tumor-suppressor genes are frequently inactivated in tumor cells, either by mutation or deletion. Thus, in normal cells a series of checks and balances must be overcome to allow initiation and continuation of cell division. In tumors, these processes are aberrant, resulting in increased rates of cell division, increases in the proportion of cells in the cell cycle, or increased survival of activated cells. Therefore, tumor cells frequently accumulate genomic alterations, which may result in the activation of a particular array of oncogenes, the inactivation of specific tumor-suppressor genes, and the bypassing of programmed cell death. Trials of antitumor agents that act by exploiting the overexpression of oncogenes in tumors and of the biochemical pathways by which they mediate cell proliferation are currently underway.

KW - Apoptosis

KW - Growth factor receptors

KW - Oncogenes

KW - Tumor-suppressor genes

UR - http://www.scopus.com/inward/record.url?scp=0027362804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027362804&partnerID=8YFLogxK

M3 - Article

C2 - 8222249

AN - SCOPUS:0027362804

VL - 39

SP - 2375

EP - 2385

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 11 PART B

ER -